United States: SEC Charges U.S. Pharmaceutical Company For FCPA Violations Arising From Alleged Bribery In China

ß

Ropes & Gray LLP

For health care companies operating in China, this case is especially noteworthy for the SEC's detailed description of the facts of the case and the Company's remedial efforts, which provide important guidance on compliance practices